Back to search results

Cevostamab with Pomalidomide and Dexamethasone for Multiple Myeloma

This study is looking at a new combination of medicines for people with multiple myeloma, a type of blood cancer. It compares a treatment called cevostamab (a monoclonal antibody, which is a type of targeted therapy) given with pomalidomide and dexamethasone, against standard care options like daratumumab or elotuzumab. You might be able to join if you are 18 or older, have multiple myeloma, and have already received one to three previous treatments, including an anti-CD38 medicine and lenalidomide. The researchers want to see how well the treatments work to reduce the cancer and how long people live without their cancer getting worse. The study plans to enroll 380 participants, but its current status is unclear.

Study design
This is an interventional study comparing different drug combinations. It plans to enroll 380 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Researchers will track how well the treatment works for up to 1 year after the last participant is randomized, and monitor progression-free survival for up to 5 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07555938

Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

Recruiting
PHASE3Ages 18+InterventionalTreatment
Hoffmann-La Roche
~380 participants
Updated 2026-08-14 on ClinicalTrials.gov
What's tested:CevostamabPomalidomideDexamethasoneDaratumumabElotuzumabCarfilzomib

At a glance

Recruiting sites
40 of 40 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Minimal Residual Disease (MRD)-Negative Complete Response (CR) Rate
Measured over Up to 1 year after the last participant is randomized
+1 more outcome measured

Conditions

Multiple Myeloma

Explore related trials

Multiple Myeloma

Where it's being run

40 sites across 19 states
Japan8
South Korea5
Germany3
Greece3
Spain3
California2
North Carolina2
Israel2

Study leadership

  • Clinical Trials · STUDY_DIRECTOR · Hoffmann-La Roche

Who to contact

Reference Study ID Number: CO46096 https://forpatients.roche.com/ No attachments to email below.
[email protected]
888-662-6728
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 at screening and immediately prior to start of administration of study treatment.
Individuals with ECOG Performance Status of 2 solely due to local symptoms of myeloma (e.g., pain) are eligible
MM diagnosis according to the International Myeloma Working Group (IMWG) diagnostic criteria
Received one to three lines of prior therapy that included at least two consecutive cycles of either of the following: A regimen containing an anti-CD38 therapy, a regimen containing lenalidomide
Participants must have measurable disease during screening

Exclusion

Known history of amyloidosis (e.g., positive Congo Red stain or equivalent in tissue biopsy or documented within serum amyloid P component scan)
Plasma cell leukemia or circulating plasma cell count exceeding 500 cells/liter (L) or 5% of the peripheral blood white cells
GI disease that might significantly alter absorption of oral drugs
Participants must not have any ongoing CNS disease or non-secretory myeloma

What this trial measures

  • Minimal Residual Disease (MRD)-Negative Complete Response (CR) RateUp to 1 year after the last participant is randomized
  • Progression-Free Survival (PFS)Up to 5 years after the last participant is randomized